VKTX

Viking Therapeutics, Inc. (VKTX) | Rumor.io

Viking Therapeutics

VKTX

Attention (50-day avg)0.06%

Attention rank (50-day avg)#146

Bullish sentiment (50-day avg)80%

Price to earnings ratio-10.4

Market capitalization4.1B

Earnings per share-4.67

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-359.6M

Social

What share of all stock conversation is about VKTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.18% 0	0.19% +0	0.09% +0.07	0.03% -0.06

Sep 29

Cantor sets a $100 price target for VKTX, citing impressive data from the Phase 3 VANQUISH study of VK2735, which exceeded Reta's treatment-regimen estimates.
VKTX has about $1 billion in cash, roughly 25% of its market capitalization, following its recent upsized offerings.
The VK2735 data may lead to a takeover, with some investors speculating that an offer from Novo or Abbvie could spark a bidding war, given the asset's potential as a highly differentiated obesity drug.

Generated by AI

Sentiment

Of the messages about VKTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	65.46% -1.47	78.28% -5.38	80.12% +0.98	80.93% +5.37
Bearish	34.54% +1.47	21.72% +5.38	19.88% -0.98	19.07% -5.37

Bullish· Sep 29

The recent selloff has been brutal, but the bigger picture is worth watching, with Viking strengthening its balance sheet while advancing a promising clinical pipeline.
The company's promising clinical pipeline, including oral VK2735 Phase 3 initiation in Q4, potential updates on VK2809 and VK3019, and possible partnership opportunities, could lead to a sustained reclaim of $35 with increasing buying volume.
Institutions loaded up at $35 and won't eat that loss, and once they report 3Q holdings, it will be clear which top shareholders are backing the truck up, indicating a strong likelihood of a bounce in the stock.

Bearish· Sep 29

The CEO of Viking Therapeutics, Inc. (VKTX) is being criticized for his management style and lack of regard for shareholders, with some accusing him of making decisions that benefit himself and the board of directors rather than the company.
The company's recent price action has been described as "beyond unreasonable" and "brutal", with some investors expressing frustration at the stock's performance and questioning the shorts' conviction in their bearish views.
There are concerns that the company's best-in-class product may not be commercialized in the near term, and that the market cap may not be reflective of the company's true value, with some investors questioning the CEO's confidence in his own conviction and the company's prospects.

Generated by AI

Topics

Of the messages about VKTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	87.86%	82.23%	56.16%	26.89%
Technical Analysis	11.56%	13.37%	10.68%	7.44%
Analysts	0.58%	1.91%	23.32%	33.49%
Earnings	0%	0%	1.71%	1.23%
Controversies	0%	2.26%	0.87%	0.87%
Macro	0%	0.23%	7.26%	30.08%

Earnings· Jul 23

Viking Therapeutics, Inc. (VKTX) reported a net loss of $0.58 per share in Q2, missing the consensus estimate of a $0.45 per share loss.
The company's operating expenses were $74.574 million in Q2, and net income was -$65.561 million, compared to the IBES estimate of -$51.6 million.
The earnings report may have led to a 6.26% decline in VKTX's stock price on Wednesday, as the company's Q2 results were considered worse than expected.

Analysts· Aug 20

Morgan Stanley reiterates a buy rating on VKTX with a $98 price target, citing significant weight loss at the highest dose.
Analysts are divided on the stock's potential, with some, like B. Riley, believing the selloff is overdone, while others, like Citigroup, have slashed their target prices.
Multiple analysts have maintained or reiterated their buy ratings on VKTX, with price targets ranging from $75 to $129, citing the drug's potential in maintenance therapy and impressive placebo-adjusted weight loss.

Announcements· Sep 28

$VKTX upsized offering closed with gross proceeds of about $575 Million, bringing current cash to close to $1 Billion.
Viking Therapeutics may hear of an offer to acquire the company for at least twice its current value, potentially in the mid-100s per share range, due to its stronger cash position.
Viking Therapeutics' ~$3.7B EV, post upsized ~$500M raise, looks heavily discounted against best-in-indication weight loss and tolerability data, according to B. Riley's $85 PT.

Technical Analysis· Sep 28

$VKTX is hitting extreme oversold levels on the hourly time frame, with previous resistance now serving as support.
The stock's volume is drying up while it's near the pivot zone, potentially indicating a reversal.
A close below $32.78 in the next two trading days in September will turn the month red, and the daily gap may need to be filled before seeing bullish momentum.

Generated by AI

Community

Of the messages about VKTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.49%	82.74%	82.01%	79.64%
Newcomers	14.51%	17.26%	17.99%	20.36%

Regulars· Sep 29

The recent equity raise by Viking Therapeutics, Inc. ($VKTX) has strengthened its balance sheet and provides negotiating power, potentially leading to a takeover bid.
The company's lead asset, VK2735, has demonstrated positive efficacy and a clean side effect profile in clinical trials, making it a promising obesity treatment.
The market is anticipating a potential bid from Novo or Abbvie, with some regulars suggesting that the company's strong financial position and favorable market conditions make it an attractive target.

Newcomers· Sep 29

The recent selloff in VKTX has been brutal, but the company has strengthened its balance sheet with a $575M financing, and a promising clinical pipeline is advancing with upcoming catalysts, including oral VK2735 Phase 3 initiation in Q4.
Many newcomers are predicting a significant price drop, with some even suggesting a price of $0, while others are calling for a price of $1000, indicating a wide range of market expectations.
The company's CEO, BL, is under fire from some shareholders who believe he has made management blunders and lacks regard for shareholders, which is affecting the stock's price action.

Generated by AI

News

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

13h agoYahoo Finance

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. | The Motley Fool

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

13h agofool.com

VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks

1d agoYahoo Finance

Viking Therapeutics raises $575 million in dual offering

1d agoInvesting.com

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

1d agoMorningstar

Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (VKTX)

Viking Therapeutics' VK2735 obesity trial shows strong weight loss and better tolerability. Read the latest analysis on the VKTX stock here.

1d agoSeeking Alpha

Also Discussed

Investors talking about VKTX also mention

#	Name	Attention
1	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
2	MTSR - Metsera, Inc.	——
3	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
4	Eli Lilly and CompanyLLY	0.16%+0.07
5	Novo Nordisk A/S Sponsored ADRNVO	0.14%-0.04
6	ETNB - 89bio, Inc.	——
7	TERN - Terns Pharmaceuticals, Inc.	——
8	Janux Therapeutics, Inc.JANX	0%0
9	SWTX - SpringWorks Therapeutics, Inc.	——
10	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91

Viking Therapeutics, Inc.

Healthcare
Biotechnology

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease. The company also works on VK0214 for X-linked adrenoleukodystrophy, VK5211 for recovery after hip fracture surgery, VK0612 for metabolic disorders and anemia, and VK3019, an amylin receptor agonist in early study. Based in San Diego, California, Viking Therapeutics is positioned as a research-focused drug developer addressing high-need areas across obesity, liver disease, rare disease, and other endocrine-related conditions.

Website

Location

9920 Pacific Heights Boulevard

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about VKTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.18% 0	0.19% +0	0.09% +0.07	0.03% -0.06

Sep 29

Cantor sets a $100 price target for VKTX, citing impressive data from the Phase 3 VANQUISH study of VK2735, which exceeded Reta's treatment-regimen estimates.
VKTX has about $1 billion in cash, roughly 25% of its market capitalization, following its recent upsized offerings.
The VK2735 data may lead to a takeover, with some investors speculating that an offer from Novo or Abbvie could spark a bidding war, given the asset's potential as a highly differentiated obesity drug.

Generated by AI

Sentiment

Of the messages about VKTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	65.46% -1.47	78.28% -5.38	80.12% +0.98	80.93% +5.37
Bearish	34.54% +1.47	21.72% +5.38	19.88% -0.98	19.07% -5.37

Bullish· Sep 29

The recent selloff has been brutal, but the bigger picture is worth watching, with Viking strengthening its balance sheet while advancing a promising clinical pipeline.
The company's promising clinical pipeline, including oral VK2735 Phase 3 initiation in Q4, potential updates on VK2809 and VK3019, and possible partnership opportunities, could lead to a sustained reclaim of $35 with increasing buying volume.
Institutions loaded up at $35 and won't eat that loss, and once they report 3Q holdings, it will be clear which top shareholders are backing the truck up, indicating a strong likelihood of a bounce in the stock.

Bearish· Sep 29

The CEO of Viking Therapeutics, Inc. (VKTX) is being criticized for his management style and lack of regard for shareholders, with some accusing him of making decisions that benefit himself and the board of directors rather than the company.
The company's recent price action has been described as "beyond unreasonable" and "brutal", with some investors expressing frustration at the stock's performance and questioning the shorts' conviction in their bearish views.
There are concerns that the company's best-in-class product may not be commercialized in the near term, and that the market cap may not be reflective of the company's true value, with some investors questioning the CEO's confidence in his own conviction and the company's prospects.

Generated by AI

Topics

Of the messages about VKTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	87.86%	82.23%	56.16%	26.89%
Technical Analysis	11.56%	13.37%	10.68%	7.44%
Analysts	0.58%	1.91%	23.32%	33.49%
Earnings	0%	0%	1.71%	1.23%
Controversies	0%	2.26%	0.87%	0.87%
Macro	0%	0.23%	7.26%	30.08%

Earnings· Jul 23

Viking Therapeutics, Inc. (VKTX) reported a net loss of $0.58 per share in Q2, missing the consensus estimate of a $0.45 per share loss.
The company's operating expenses were $74.574 million in Q2, and net income was -$65.561 million, compared to the IBES estimate of -$51.6 million.
The earnings report may have led to a 6.26% decline in VKTX's stock price on Wednesday, as the company's Q2 results were considered worse than expected.

Analysts· Aug 20

Morgan Stanley reiterates a buy rating on VKTX with a $98 price target, citing significant weight loss at the highest dose.
Analysts are divided on the stock's potential, with some, like B. Riley, believing the selloff is overdone, while others, like Citigroup, have slashed their target prices.
Multiple analysts have maintained or reiterated their buy ratings on VKTX, with price targets ranging from $75 to $129, citing the drug's potential in maintenance therapy and impressive placebo-adjusted weight loss.

Announcements· Sep 28

$VKTX upsized offering closed with gross proceeds of about $575 Million, bringing current cash to close to $1 Billion.
Viking Therapeutics may hear of an offer to acquire the company for at least twice its current value, potentially in the mid-100s per share range, due to its stronger cash position.
Viking Therapeutics' ~$3.7B EV, post upsized ~$500M raise, looks heavily discounted against best-in-indication weight loss and tolerability data, according to B. Riley's $85 PT.

Technical Analysis· Sep 28

$VKTX is hitting extreme oversold levels on the hourly time frame, with previous resistance now serving as support.
The stock's volume is drying up while it's near the pivot zone, potentially indicating a reversal.
A close below $32.78 in the next two trading days in September will turn the month red, and the daily gap may need to be filled before seeing bullish momentum.

Generated by AI

Community

Of the messages about VKTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.49%	82.74%	82.01%	79.64%
Newcomers	14.51%	17.26%	17.99%	20.36%

Regulars· Sep 29

The recent equity raise by Viking Therapeutics, Inc. ($VKTX) has strengthened its balance sheet and provides negotiating power, potentially leading to a takeover bid.
The company's lead asset, VK2735, has demonstrated positive efficacy and a clean side effect profile in clinical trials, making it a promising obesity treatment.
The market is anticipating a potential bid from Novo or Abbvie, with some regulars suggesting that the company's strong financial position and favorable market conditions make it an attractive target.

Newcomers· Sep 29

The recent selloff in VKTX has been brutal, but the company has strengthened its balance sheet with a $575M financing, and a promising clinical pipeline is advancing with upcoming catalysts, including oral VK2735 Phase 3 initiation in Q4.
Many newcomers are predicting a significant price drop, with some even suggesting a price of $0, while others are calling for a price of $1000, indicating a wide range of market expectations.
The company's CEO, BL, is under fire from some shareholders who believe he has made management blunders and lacks regard for shareholders, which is affecting the stock's price action.

Generated by AI

Viking Therapeutics

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Jul 23

Analysts· Aug 20

Announcements· Sep 28

Technical Analysis· Sep 28

Regulars· Sep 29

Newcomers· Sep 29

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. | The Motley Fool

VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks

Viking Therapeutics raises $575 million in dual offering

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (VKTX)

Also Discussed

Viking Therapeutics, Inc.

Company Information

Location

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. | The Motley Fool

VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks

Viking Therapeutics raises $575 million in dual offering

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (VKTX)

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Earnings· Jul 23

Analysts· Aug 20

Announcements· Sep 28

Technical Analysis· Sep 28

Regulars· Sep 29

Newcomers· Sep 29